Delving into the Latest Updates on Nilotinib Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Nilotinib, nilotinib D-tartrate, Nilotinib Hydrochloride Hydrate

+ [15]

Target

CSF-1R x DDR1 x c-Kit

Action

antagonists, inhibitors

Mechanism

CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists), DDR1 antagonists(Discoidin domain receptor 1 antagonists), c-Kit inhibitors(Stem cell growth factor receptor inhibitors)

Therapeutic Areas

NeoplasmsHemic and Lymphatic DiseasesNervous System Diseases+ [5]

Active Indication

Aggressive-Phase Chronic Myelocytic LeukemiaAccelerated phase Philadelphia chromosome positive chronic myeloid leukemiaPhiladelphia chromosome-positive chronic myeloid leukemia in chronic phase+ [11]

Inactive Indication

Acoustic NeuromaAcral Lentiginous Malignant MelanomaAcute Myeloid Leukemia+ [41]

Originator Organization

Novartis Pharma AG

Active Organization

Novartis Europharm Ltd.Novartis Pharma Services AG

Novartis Pharmaceuticals Corp.

+ [14]

Inactive Organization

Novartis Farmacéutica SANovartis Farma

Novartis Pharma Stein AG

+ [1]

License Organization-

Drug Highest PhaseApproved

First Approval Date

Switzerland (24 Jul 2007),

Philadelphia chromosome positive chronic myelogenous leukemia

RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (Japan)

Login to view timeline

Structure/Sequence

Molecular FormulaC28H25ClF3N7O2

InChIKeyYCBPQSYLYYBPDW-UHFFFAOYSA-N

CAS Registry923288-90-8

The goal of this clinical trial is to learn if Asciminib, a first in class allosteric inhibitor, as a add-on maintenance therapy can provides benefits and further prevents relapse in post allogenic hematopoietic stem-cell transplant (HSCT) of patients with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL) or blastic transformed Chronic Myeloid Leukemia (CML-BP).
The main questions it aims to answer are:
Would Ascminib add-on maintenance therapyimprove Morphological relapse-free survival rate? Would Ascminib add-on maintenance therapy improve Molecular relapse-free survival and Overall survival ? Any toxicity or intolerable events during Ascminib add-on maintenance therapy?
Researchers will compare Study arm (Ascminib plus tyrosine-kinase inhibitors [TKIs]) and Control arm (TKIs only) to see if Ascminib add-on maintenance therapy would provide better relapse-free survival (RFS) with optimal tolerability.
Participants will
* Enrolled and Randomized into either Study arm or Control arm
* Take Ascminib plus selected TKI or selected TKI only according to schedule
* Visit the clinic once every 2-4 weeks for checkups and tests
* Record and Report any adverse event and graft-versus-host-disease (GvHD) development

Start Date30 Mar 2026

Sponsor / Collaborator

The University of Hong Kong

[+2]

NL-OMON57005

/ SuspendedNot ApplicableIIT

Microsampling for therapeutic drug monitoring of imatinib, dasatinib, nilotinib, gilteritinib, midostaurin, and venetoclax - Microsampling Oral Oncolytics

Start Date01 Feb 2026

Sponsor / Collaborator-

100 Clinical Results associated with Nilotinib Hydrochloride

Login to view more data

100 Translational Medicine associated with Nilotinib Hydrochloride

Login to view more data

100 Patents (Medical) associated with Nilotinib Hydrochloride

Login to view more data

3,817

Literatures (Medical) associated with Nilotinib Hydrochloride

01 Dec 2026·Clinical Proteomics

A succinylation-related prognostic model for predicting lung adenocarcinoma prognosis and guiding immunotherapy

Article

Author: Li, Zongyu ; Liu, Qingqing ; Zhang, Tiantian ; Zhu, Yan ; Lu, Erdan

BACKGROUND:

Lung adenocarcinoma (LUAD) is a common culprit of cancer-related deaths. Recent studies have revealed that succinylation-related genes (SRGs) are pivotal in cancer. However, the comprehensive characteristics and clinical significance of SRGs in LUAD occurrence are not clear. Therefore, our goal is to dig out the succinylation-related prognostic feature genes in LUAD.

METHODS:

We identified differentially expressed SRGs in LUAD, and established the LUAD prognostic model using analyses of multivariate, LASSO, and univariate Cox regression. Based on clinical information and riskscore, we graphed a nomogram of the prognostic model and analyzed the independent prognostic ability of the riskscore. Analyses of immune assessment, mutation frequency, and drug sensitivity were carried out on LUAD patients.

RESULTS:

A 9-gene prognostic model was successfully set up in this project. The receiver operation characteristic (ROC) curves illustrated that the model effectively predicted the risk of LUAD patients. The levels of immune infiltration and immune scores of LUAD patients in the high-risk (HR) group were greatly lower than those in the low-risk (LR) group. Furthermore, compared to the LR group, the HR group had a significantly elevated gene mutation rate. ENPP3 and SLC22A8 may respond to targeted drugs more sensitively. The low-expression groups of ENPP3 and SLC22A8 genes may have higher drug sensitivity to Nilotinib, ARRY-614, and Megestrol acetate, with lower drug resistance.

CONCLUSION:

The above results indicated that the prognostic model established using SRGs can be a predictive marker for LUAD prognosis, offering references for LUAD treatment and evaluation.

01 Apr 2026·CURRENT OPINION IN NEUROBIOLOGY

The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease

Review

Author: Huot, Philippe ; Teil, Margaux

An important part of the field of experimental pharmacology encompasses the study of the effects of molecules in animals. In the case of Parkinson's disease (PD), animal models have played an invaluable role in refining our understanding of the disease, in characterizing the effect of new compounds on the illness, and in bringing new treatments to the clinic. Indeed, it is now hardly conceivable that a drug would be tested in humans if several parameters pertaining to safety, toxicology, efficacy, etc. had not previously been evaluated in animal models. Quite unfortunately, efficacy in experimental models of PD does not necessarily guarantee positive clinical outcomes. In this article, which primarily focusses on the past five years, we review drugs that entered clinical trials for the treatment of levodopa-induced dyskinesia, parkinsonism, disease modification, and had previously been assessed in animal models of PD. The drugs discussed are buspirone, JM-010, befiradol, mesdopetam, foliglurax, dipraglurant, tavapadon, prasinezumab, cinpanemab, nilotinib, minzasolmin, exenatide, NLY01, liraglutide, lixisenatide, and semaglutide. For each molecule, we examine how previous preclinical studies succeeded or failed in predicting efficacy in clinical trials and discuss possible ways to optimize animal-model design and selection to maximize the probability of translational success.

01 Mar 2026·BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Pharmacokinetic Determinants of Ponatinib‐Induced Vascular Toxicity: A Possible Role of Perivascular Adipose Tissue

Article

Author: Kurylowicz, Zuzanna ; Benbouziane, Iwaine ; Buczek, Elzbieta ; Gdula, Anna ; Bar, Anna ; Chlopicki, Stefan ; Marczyk, Brygida ; Kij, Agnieszka ; Czamara, Krzysztof ; Karas, Agnieszka

ABSTRACT:

Tyrosine kinase inhibitors (TKIs) have revolutionised chronic myeloid leukaemia treatment but cause cardiovascular toxicities through incompletely understood mechanisms. This study characterised the pharmacokinetics of imatinib, nilotinib and ponatinib, focusing on perivascular adipose tissue (PVAT) accumulation and vascular toxicity in C57BL/6 mice. Ponatinib showed unique pharmacokinetics with high apparent mean residence time (5.22 h vs. 1.51 h for imatinib, and 3.20 h for nilotinib) and high apparent distribution volume (2891.33 mL/kg vs. 683.75 mL/kg for imatinib, and 74.84 mL/kg for nilotinib). Importantly, ponatinib had exceptionally high tissue‐to‐plasma ratio in aorta with PVAT (8.44 vs. 0.37 for imatinib, and 0.14 for nilotinib). Chronic ponatinib treatment (10 mg/kg, 4 weeks) severely impaired endothelium‐dependent vasodilation assessed by magnetic resonance imaging in vivo (thoracic aorta −7.4 ± 1.1% vs. controls 5.1 ± 1.3%). Ponatinib accumulated in aorta with PVAT after chronic treatment and directly impaired adipocyte maturation in in vitro experiments. In isolated aorta, ponatinib reduced vascular nitric oxide (NO) release. In conclusion, endothelial dysfunction and impaired NO‐dependent function induced by ponatinib were related to a unique profile of ponatinib distribution compared with other TKIs, along with direct effects on adipocyte maturation. Our results suggest that after chronic treatment, ponatinib accumulation in PVAT leads to the impairment of the vasoprotective function of PVAT, contributing to endothelial dysfunction induced by ponatinib.

117

News (Medical) associated with Nilotinib Hydrochloride

25 Mar 2026

·allsci.com

Merck acquires Terns for USD 6.7b to boost hematology pipeline with CML drug

Merck (NYSE: MRK) has entered into a definitive agreement to acquire Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage oncology company, for USD 53.00 per share in an all-cash transaction valued at approximately USD 6.7 billion. The Merck Terns Pharmaceuticals acquisition positions the pharma company to consolidate its presence in hematology through TERN-701, an oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase I/II development for chronic myeloid leukemia. The transaction represents approximately USD 5.7 billion net of acquired cash and carries a premium of 31% to the 60-day and 42% to the 90-day volume-weighted average stock price as of March 24, 2026. The deal contains no disclosed milestone payments, contingent value rights, or earn-out provisions. Merck will execute the acquisition through a tender offer requiring a majority of Terns stockholders to tender their shares, with closing expected in Q2 2026 following expiration of the Hart-Scott-Rodino waiting period. The transaction will be accounted for as an asset acquisition, resulting in an approximately USD 5.8 billion charge (approximately USD 2.35 per share) recognized in both Q2 and full-year 2026 GAAP and non-GAAP results. The asset acquisition classification means the acquired in-process R&D will be expensed immediately rather than capitalized. TERN-701: Mechanism and clinical status TERN-701 is a BCR-ABL1 tyrosine kinase inhibitor designed to bind to the ABL myristoyl pocket, an allosteric site distinct from the ATP-binding domain targeted by earlier-generation TKIs. CML is driven by the Philadelphia chromosome, a translocation between chromosomes 9 and 22 that produces constitutive activation of the BCR::ABL1 fusion protein, which fuels malignant white blood cell proliferation. The compound is being evaluated in the CARDINAL trial (NCT06163430), a global multi-center dose escalation and expansion study enrolling patients with Ph+ chronic phase CML who experienced treatment failure, suboptimal response, or intolerance to at least one prior TKI. The dose escalation portion completed in January 2025 with no dose-limiting toxicities observed up to 500 mg QD. Dose expansion initiated in April 2025 across two cohorts (320 mg and 500 mg QD), and in January 2026 an additional cohort was added to evaluate activity against BCR::ABL1 resistance mutations including T315I, M244V, and F359I/C/V. The FDA granted Orphan Drug Designation for TERN-701 in CML in March 2024. Clinical data reported to date indicate rates of major molecular response and deep molecular response by week 24, including in patients with high disease burden who had received multiple prior therapy lines, with low rates of severe adverse events and discontinuations. Specifically, Terns reported a 75% cumulative MMR rate by 24 weeks in 32 efficacy-evaluable patients. The strategic context The TERN-701 CML program joins a Merck hematology pipeline that already includes three Phase III candidates: bomedemstat (LSD1 inhibitor), nemtabrutinib (non-covalent BTK inhibitor), and zilovertamab vedotin (ROR1-targeting ADC), along with MK-1045 (CD19×CD3 T-cell engager) in Phase Ib/II. The Terns buyout extends a pattern of aggressive deal-making driven by the approaching Keytruda patent cliff (~2028). Merck’s recent transactions include the USD 9 billion purchase of influenza-focused Cidara Therapeutics, Inc. (Nasdaq: CDTX), the USD 10 billion purchase of Verona Pharma for a COPD therapy, and the USD 10.8 billion acquisition of immunology-focused Prometheus Biosciences. In the chronic myeloid leukemia treatment landscape, TERN-701 enters a competitive field. Novartis markets asciminib (Scemblix), the first approved allosteric BCR::ABL1 inhibitor, which received FDA approval in 2022 for Ph+ CML after two or more prior TKIs and gained a first-line CML indication based on the ASC4FIRST trial. Sun Pharma Advanced Research is developing denimsertib, another allosteric BCR::ABL1 inhibitor in clinical development. Earlier-generation ATP-competitive TKIs from Novartis (imatinib, nilotinib), Bristol Myers Squibb (dasatinib), and Pfizer (bosutinib) remain standards of care, though resistance mutations and tolerability limitations persist across these agents. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

AcquisitionOrphan DrugClinical ResultDrug ApprovalPhase 3

04 Feb 2026

·endpoints.news

Updated: Novartis expects generics to shave $4B from 2026 sales, as Entresto takes Q4 hit

Novartis said further generic erosion of three blockbuster medicines, including its top-selling heart failure drug Entresto, will leave a $4 billion hole in its sales this year. Generic competition started to make a mark in the fourth quarter, as Entresto sales plummeted 45% from the year-earlier period in constant currencies to $1.25 billion. Sales of thrombocytopenia treatment Promacta plunged 63% to $226 million, while blood cancer drug Tasigna declined 58% to $179 million. Even with the three generic rivals entering the market around mid-2025, Novartis was able to produce total fourth-quarter sales of $13.3 billion, relatively steady compared to the previous year. As for the coming full year, the company is predicting an increase in the low-single digits. “We expect to grow in 2026 through the largest patent expiries in Novartis history,” CEO Vas Narasimhan told the media. “This demonstrates the strength of our growth drivers and the strength of our pipeline.” Novartis’ revenue forecast suggests 2026 sales of $56.2 billion to $57.9 billion, Jefferies analysts wrote in a same-day note. At the same time, Novartis foresees core operating income declining by low-single digits, according to its latest earnings report . Full-year 2025 sales were up 8% from the year before, at $54.5 billion, supported by two products that passed the $1 billion mark for the first time. Blood cancer drug Scemblix pulled in $1.29 billion in 2025, up 85% from 2024. And sales of cholesterol medicine Leqvio grew 57% to hit $1.19 billion. Investors seemed to be reassured by these figures. The company’s share price remained flat on the Swiss exchange early Wednesday. On the pipeline side, Novartis discontinued several early- to mid-stage programs following a review. The majority of culled candidates were in Phase 1 development for cancer, namely: Novartis also dropped a candidate for tendinopathy called NGI226 that was in Phase 2 development. A company spokesperson wrote in an email that the cuts were “balanced by the addition of new projects entering our pipeline.” Novartis also slightly delayed some of its highly anticipated R&D milestones. It now expects to report Phase 3 data for pelacarsen in this year’s second half, as opposed to the first half, according to an earnings presentation . The drug is for certain patients who have elevated levels of lipoprotein(a). The company also said Phase 3 data for its rare kidney disease drug zigakibart would come in the first half of 2027, instead of this year. Novartis amended the protocol of a trial in IgA nephropathy so that kidney biomarker data would come at the same time as results on the primary endpoint of proteinuria, which is considered a more robust marker of kidney function. Elsewhere, Narasimhan said Novartis was still “very active” when it came to deals in China. Last month, it spent $50 million upfront to license a radiopharmaceutical candidate from Zonsen PepLib Biotech. Oncology will be a core focus for Novartis’ M&A deals going forward, Narasimhan told analysts on a separate earnings call. On the media call, the CEO described China’s biotech environment as “very important” and “exciting,” adding that US and European regulators could take lessons from some of the ways China has “streamlined regulatory oversight” and “modernized its clinical trial enrollment approach.” Novartis isn’t the first company to double down on its interest in China. Last month, AstraZeneca announced it would spend $15 billion on manufacturing and R&D projects in China through 2030. In December, Novartis said it had reached a deal with President Donald Trump’s administration to lower drug prices in the US. That deal included an agreement to launch future medicines with “comparable prices” across high-income countries. Narasimhan told analysts the company is “working through strategies” for anticipated launches, including its Sjögren’s disease candidate ianalumab, which is expected to launch in the G7 countries next year. Editor’s note: This article was updated to add comments from Novartis’ analyst call.

Phase 3Phase 2

04 Feb 2026

·firstwordpharma.com

'Largest patent expiry' in Novartis' history to wipe $4B from sales this year

Novartis chief executive Vas Narasimhan said Thursday that "the largest patent expiry" in the company's history will wipe out $4 billion in sales in 2026, although overall revenue is still predicted to grow this year in the low single-digits on a constant currency basis. Generic competition to Entresto, Tasigna and Promacta entered the US in 2025, leading to sharp declines in sales of the products in the second half of the year.This is expected to continue in the first half of 2026. "This creates, of course, a full-year effect that comes mainly in half one," explained Chief Financial Officer Harry Kirsch.Kirsch — speaking on a media call — echoed Narasimhan's assessment, calling it "the biggest generic effect that we ever had in the last 20 years." However, he said in terms of guidance, it's "easy to model" the impact. "You take the US sales…of last year first half. And then you see that basically most of this goes away fully as of half one this year. And so it's really an achievement to grow the company."Despite the expected uptick in sales this year, which will be led by Novartis' current growth drivers — Kisqali, Kesimpta, Pluvicto, Scemblix and Cosentyx — core operating income is predicted to decline in the low single-digits on a constant currency basis.Two new blockbustersContributing to 2026 growth will be two newly-crowned blockbuster products, with sales from both Leqvio and Scemblix crossing the $1-billion threshold for the first time in 2025. Revenue from the lipid-lowering drug Leqvio jumped 59% last year to $1.2 billion, while sales of chronic myeloid leukaemia treatment Scemblix surged 87% to $1.3 billion.Narasimhan said that while Leqvio has benefited from "solid, but not spectacular growth in the US," its performance in other markets, particularly in China, has driven growth. The product recently received NRDL listing in China, which Narasimhan suggested will "be a significant accelerant…for the brand."Meanwhile, Narasimhan noted that Scemblix has posted "very strong growth," with the company remaining confident that the drug could generate peak sales of over $4 billion. "So both of these medicines will be very important for our growth through the end of the decade, but also into the middle of the 2030s," Narasimhan said.The performance of Leqvio and Scemblix, coupled with Novartis' other growth drivers, propelled sales in 2025 up 8% to $50.3 billion, while net income rose 17% to $11.9 billion.Revenue growth was more muted in the final quarter of the year, rising 1% to $13.3 billion, with generic competition having a negative impact of 15 percentage points. Sales of Entresto fell 43% in the fourth quarter to $1.3 billion, Promacta was down 61% to $226 million and Tasigna slipped 56% to $179 million.In contrast, three-month revenue from Cosentyx increased 13% to $1.8 billion; Kisqali grew 46% to $1.3 billion; Kesimpta was up 29% to $1.2 billion; and Pluvicto lifted 72% to $605 million.

BiosimilarPatent Expiration

100 Deals associated with Nilotinib Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D06413	Nilotinib Hydrochloride	L01XE08	DB04868

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Aggressive-Phase Chronic Myelocytic Leukemia	United States	Novartis Pharmaceuticals Corp.	22 Jan 2014
Accelerated phase Philadelphia chromosome positive chronic myeloid leukemia	United States	Novartis Pharmaceuticals Corp.	29 Oct 2007
Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase	United States	Novartis Pharmaceuticals Corp.	29 Oct 2007
Philadelphia chromosome positive chronic myelogenous leukemia	Switzerland	Novartis Pharma Schweiz AG	24 Jul 2007

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic phase chronic myeloid leukemia	NDA/BLA	European Union	Novartis Europharm Ltd.	27 Jun 2024
Alzheimer Disease	Phase 3	-	KeifeRx LLC	01 Feb 2022
Chronic Myelogenous Leukemia	Phase 3	China	Novartis Pharmaceuticals Corp.	01 Apr 2011
Metastatic melanoma	Phase 3	Belgium	Novartis Pharma Services AG	16 Apr 2010
Leukocytosis	Phase 3	Spain	Novartis Farmacéutica SA	04 Dec 2009
Cerebral Palsy	Phase 3	South Korea	Novartis AG	01 Jan 2009
Metastatic Gastrointestinal Stromal Tumor	Phase 3	Germany	Novartis Pharmaceuticals Corp.	01 Nov 2008
Metastatic Gastrointestinal Stromal Tumor	Phase 3	Italy	Novartis Pharmaceuticals Corp.	01 Nov 2008
Leukemia	Phase 3	Slovakia	Novartis Pharma Services AG	20 Apr 2007
Gastrointestinal Stromal Tumors	Phase 3	United States	Novartis Pharmaceuticals Corp.	01 Mar 2007

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02001818 \| ACTRN12612000851864 (CML11, Pubmed) Manual	Phase 2	Chronic phase chronic myeloid leukemia First line	60	peginterferon alfa-2b + Nilotinib	icsnlfbobd(ahyucnsrfz) = bteebaunpd zthaqrdbxf (fbjenqjrkk ) View more	Positive	22 Dec 2025
NCT03654768 (CTgov)	Phase 2	Chronic phase chronic myeloid leukemia	81	dasatinib+nilotinib+imatinib+bosutinib (Single Agent TKI)	xfiwfsrubt = buycmrjsme yhafzibnwr (ubmelapjmu, gaweyiycem - xgjjbojods) View more	-	18 Dec 2025
				Ruxolitinib (TKI + Ruxolitinib)	xfiwfsrubt = dggfgcsoah yhafzibnwr (ubmelapjmu, mhqviydmdr - tmyassgemm) View more
NCT02602314 (SUSTRENIM, ASH2025)	Phase 3	Chronic Myelogenous Leukemia First line	448	Nilotinib	drbochmtou(glybboguup) = duwecqbuft xvnuaxdlfy (eqrrkrotzj, 65.1 - 86.5) View more	Positive	06 Dec 2025
				Imatinib	drbochmtou(glybboguup) = qirqwgwvss xvnuaxdlfy (eqrrkrotzj, 44.0 - 69.3) View more
ASH2025	Not Applicable	Chronic phase chronic myeloid leukemia	530	imatinib	oyttxgdlwp(zbpzkgwsss) = tyfncxvzua ykkvnmlcza (vpigbbyrbv ) View more	Positive	06 Dec 2025
				nilotinib	oyttxgdlwp(zbpzkgwsss) = emswpjybpz ykkvnmlcza (vpigbbyrbv ) View more
ASH2025	Not Applicable	Chronic phase chronic myeloid leukemia First line	270	Flumatinib	mbpuvfdcmn(uqcvvobaek) = qbudqnbori blryxjhwma (mtedwlazbm ) View more	Positive	06 Dec 2025
				Nilotinib	mbpuvfdcmn(uqcvvobaek) = ucdoukefgn blryxjhwma (mtedwlazbm ) View more
ASH2025	Not Applicable	-	212	Intensive Chemotherapy (IC)	jdwooeuurv(wicybdmjyh) = udxmuterog nmiiuntrno (xqucovlcpt ) View more	Positive	06 Dec 2025
				Intensive Chemotherapy + Tyrosine Kinase Inhibitor (IC + TKI)	jdwooeuurv(wicybdmjyh) = nvwsvuzcoh nmiiuntrno (xqucovlcpt ) View more
ASH2025	Not Applicable	Philadelphia positive acute lymphocytic leukaemia	958	imatinib	joaylcuzlx(teomgkzsns) = jzgchbqknm abqtiwodne (btjukncwel ) View more	Positive	06 Dec 2025
				dasatinib	joaylcuzlx(teomgkzsns) = snfbedxaxv abqtiwodne (btjukncwel ) View more
NCT04205903 (CTgov)	Phase 1	Breast Cancer \| Peripheral Nervous System Diseases	11	Questionnaire Administration+Nilotinib Hydrochloride Monohydrate+Paclitaxel (Dose Level 1)	mqabrmvatb(pcfyglasvf) = nzkglzzsdy ivqfdhgkfz (tqfghbwygl, uwzzerwavo - yvhabsjndh) View more	-	29 Jun 2025
				Questionnaire Administration+Nilotinib Hydrochloride Monohydrate+Paclitaxel (Dose Level 2)	mqabrmvatb(pcfyglasvf) = tfbqbsqtbj ivqfdhgkfz (tqfghbwygl, hvtlbgzlkp - xbsinojwdy) View more
NCT04449549 (RARE CANCER 1, ASCO2025)	Phase 2	Solid tumor	31	Nilotinib 300 mg	lpvskthrlm(wvfeepeayz) = dduxomnwlp rhtidkghon (myosdieafk ) View more	Positive	30 May 2025
EHA2025	Phase 3	Chronic Myelogenous Leukemia	432	Nilotinib 300 mg BID	nqtprwsbzy(ndpgmcqyog) = sqbnuovvvz mfldlznecn (tfguzoyrmz )	-	14 May 2025
				Dasatinib 100 mg QD	nqtprwsbzy(ndpgmcqyog) = bdhfkzvefp mfldlznecn (tfguzoyrmz )